Kite, a Gilead company, has unveiled promising real-world data at the 2025 American Society of Clinical Oncology Annual Meeting regarding the use of Yescarta® (axicabtagene ciloleucel) for patients with relapsed/refractory large B-cell lymphoma. The study compared patients treated in outpatient settings to those in inpatient settings and found similar safety and effectiveness outcomes. This suggests that outpatient administration could be a viable and safe option, providing benefits for patients, families, and the healthcare system by reducing hospital burdens. The findings are based on data from the Center for International Blood and Marrow Transplant Research registry and support expanding the use of Yescarta, a one-time treatment with curative potential, in suitable conditions.